Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects

被引:85
作者
Cheung, WK
Goon, BL
Guilfoyle, MC
Wacholtz, MC
机构
[1] RW Johnson Pharmaceut Res Inst, Dept Drug Metab, Raritan, NJ 08869 USA
[2] RW Johnson Pharmaceut Res Inst, Dept Global Clin Res & Dev, Raritan, NJ 08869 USA
关键词
D O I
10.1016/S0009-9236(98)90072-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To understand the pharmacokinetic and pharmacodynamic properties of recombinant human erythropoietin (epoetin alfa) and to continue to optimize dosing regimens by determining whether administration of single high doses of epoetin alfa is as effective as repeated administration. Methods: Epoetin alfa was administered as single subcutaneous doses of 300, 450, 600, 900, 1200, 1350, 1800, and 2400 IU/kg and in multiple subcutaneous dose regimens: 150 IU/kg 3 times a week for 4 weeks and 600 IU/kg once per week for 4 weeks in 2 open-label, randomized placebo-controlled studies in healthy volunteers. Results: The absorption rate of epoetin alfa after subcutaneous administration was independent of dose, whereas clearance was dose-dependent in that it decreased with increasing dose. There was a linear relationship between response measured as percentage of reticulocytes area under the curve (AUC) and erythropoietin AUC for single doses up to 1800 IU/kg. Beyond the 1800 IU/kg dose, there was a saturation of response. The mean percentage of reticulocytes after single-dose regimens began to increase by days 3 to 4, reached their maximum at days 8 to 11, and returned to baseline values by day 22. In contrast, the mean percentage of reticulocytes after both multiple-dose regimens were maintained above baseline values through day 22 as both regimens stimulated modest but sustained increases in percentage of reticulocytes (1% to 2%). The mean percentage of reticulocytes AUC for 600 IU/kg epoetin alfa given once a week for 4 weeks was apparently greater than the mean percentage of reticulocytes AUC for 150 IU/kg 3 times a week for 4 weeks. Although daily oral iron supplementation was given, mean serum ferritin levels declined by approximately 75% through day 22 in subjects treated with multiple doses of epoetin alfa. Conclusions: These findings show that the pharmacologic response to epoetin alfa is a function of dose and dosing regimen. Repeated administration of epoetin alfa was more effective in stimulating a reticulocyte response than single-dose administration of the same total amount of epoetin alfa.
引用
收藏
页码:412 / 423
页数:12
相关论文
共 22 条
[1]   INTRAVENOUS VERSUS SUBCUTANEOUS DOSING OF EPOETIN - A REVIEW OF THE LITERATURE [J].
ASHAI, NI ;
PAGANINI, EP ;
WILSON, JM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 22 (02) :23-31
[2]  
BARCLAY PG, 1993, CLIN NEPHROL, V40, P277
[3]  
DANIELSON BG, 1988, 2ND INV M R HU EPO V, P3
[4]   EFFECT OF PURE ERYTHROPOIETIN ON DNA-SYNTHESIS BY HUMAN MARROW DAY 15 ERYTHROID BURST FORMING UNITS IN SHORT-TERM LIQUID CULTURE [J].
DESSYPRIS, EN ;
KRANTZ, SB .
BRITISH JOURNAL OF HAEMATOLOGY, 1984, 56 (02) :295-306
[5]  
EGRIE J C, 1988, Kidney International, V33, P262
[6]   PHARMACOKINETICS AND ERYTHROPOIETIC RESPONSE TO HUMAN RECOMBINANT ERYTHROPOIETIN IN HEALTHY-MEN [J].
FLAHARTY, KK ;
CARO, J ;
ERSLEV, A ;
WHALEN, JJ ;
MORRIS, EM ;
BJORNSSON, TD ;
VLASSES, PH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (05) :557-564
[7]  
GRUNE W, 1996, ATLAS AUTOMATED CYTO, V94, P1
[8]  
HUSSEIN S, 1975, BRIT MED J, V1, P546, DOI 10.1136/bmj.1.5957.546
[9]   ISOLATION AND CHARACTERIZATION OF GENOMIC AND CDNA CLONES OF HUMAN ERYTHROPOIETIN [J].
JACOBS, K ;
SHOEMAKER, C ;
RUDERSDORF, R ;
NEILL, SD ;
KAUFMAN, RJ ;
MUFSON, A ;
SEEHRA, J ;
JONES, SS ;
HEWICK, R ;
FRITSCH, EF ;
KAWAKITA, M ;
SHIMIZU, T ;
MIYAKE, T .
NATURE, 1985, 313 (6005) :806-810
[10]   ERYTHROPOIETIN - STRUCTURE, CONTROL OF PRODUCTION, AND FUNCTION [J].
JELKMANN, W .
PHYSIOLOGICAL REVIEWS, 1992, 72 (02) :449-489